Peptide receptor radionuclide therapy in neuroendocrine tumours: advances, combination strategies, and future directions.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Peptide receptor radionuclide therapy in neuroendocrine tumours: advances, combination strategies, and future directions.
- Published In:
- European journal of nuclear medicine and molecular imaging (2026)
- Authors:
- Virgolini, Irene J, Di Santo, Gianpaolo(2), Santo, Giulia(2)
- Database ID:
- RPEP-16322
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-16322APA
Virgolini, Irene J; Di Santo, Gianpaolo; Santo, Giulia. (2026). Peptide receptor radionuclide therapy in neuroendocrine tumours: advances, combination strategies, and future directions.. European journal of nuclear medicine and molecular imaging. https://doi.org/10.1007/s00259-025-07750-w
MLA
Virgolini, Irene J, et al. "Peptide receptor radionuclide therapy in neuroendocrine tumours: advances, combination strategies, and future directions.." European journal of nuclear medicine and molecular imaging, 2026. https://doi.org/10.1007/s00259-025-07750-w
RethinkPeptides
RethinkPeptides Research Database. "Peptide receptor radionuclide therapy in neuroendocrine tumo..." RPEP-16322. Retrieved from https://rethinkpeptides.com/research/virgolini-2026-peptide-receptor-radionuclide-therapy
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.